• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >Lipoplatin Treatment in Lung and Breast Cancer
【24h】

Lipoplatin Treatment in Lung and Breast Cancer

机译：脂铂治疗肺癌和乳腺癌

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The introduction of cisplatin in cancer treatment represents an important achievement in the oncologic field. Many types of cancers are now treated with this drug, and in testicular cancer patients major results are reached. Since 1965, other compounds were disovered and among them carboplatin and oxaliplatin are the main Cisplatin analogues showing similar clinical efficacy with a safer toxicity profile. Lipoplatin is a new liposomal cisplatin formulation which seems to have these characteristics. Lipoplatin was shown to be effective in NSCLC both in phase 2 and phase 3 trials, with the same response rate of Cisplatin, a comparable overall survival but less toxicity. A new protocol aiming to elucidate the double capacity of Lipoplatin to act as a chemotherapeutic and angiogenetic agent in triple-negative breast cancer patients is upcoming.
机译：在癌症治疗中引入顺铂代表了肿瘤学领域的重要成就。现在，这种药物可以治疗多种类型的癌症，在睾丸癌患者中可以达到主要结果。自1965年以来，其他化合物被取代，其中卡铂和奥沙利铂是主要的顺铂类似物，显示出相似的临床疗效和更安全的毒性。脂铂是一种新的脂质体顺铂制剂，似乎具有这些特征。脂铂在2期和3期试验中均显示出对NSCLC有效，顺铂的缓解率相同，总体生存率相当，但毒性较小。旨在阐明脂铂在三阴性乳腺癌患者中作为化学治疗和血管生成剂的双重能力的新方案即将出台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号